Caster and colleagues reported that pretreatment with veliparib (a PARP inhibitor) significantly augmented the increase in major histocompatibility complex class I (MHC-I) and PD-L1 expression in CT26 and MC38 tumours treated with IR. This evidence concerns the gene CD274 and neoplasm.